Manos N, Gkiouzepas J, Tzotzoras T, Tzanetoglou A
J Nerv Ment Dis. 1981 Oct;169(10):659-61. doi: 10.1097/00005053-198110000-00010.
Twenty-four months after the completion of a double blind study of antiparkinson (AP) medication abrupt withdrawal in which 100 chronic schizophrenics took part, 42 patients out of that study's 75 patient placebo group were found in the ward. In a new double blind 8-week study of 3-week gradual withdrawal of AP medication, 70-6 per cent of the 34 patient placebo group (vs. none of the active) presented severe extrapyramidal symptoms (EPS) necessitating early termination, 23.5 per cent (vs. 12.5 per cent of the active) presented worsening but not to a point necessitating early termination, and only 5.9 per cent (vs. 87.5 per cent of the active) completed the 8-week period unchanged. Furthermore, 41.17 and 23.52 per cent of the placebo group (vs none of the active) presented EPS-related severe complaints and or psychotic symptomatology, respectively. These results were almost identical to those of the study of abrupt withdrawal. Thus, it seems that AP medication withdrawal in chronic schizophrenics remains problematic, even if the medication is withdrawn gradually.
在一项针对100名慢性精神分裂症患者参与的抗帕金森（AP）药物突然停药的双盲研究完成24个月后，在该研究的75名患者安慰剂组中有42名患者被发现在病房。在一项新的为期8周的双盲研究中，对AP药物进行3周逐渐停药，34名患者安慰剂组中有70.6%（与之相比，活性药物组无一人出现）出现严重锥体外系症状（EPS），需要提前终止研究，23.5%（与之相比，活性药物组为12.5%）症状恶化但未达到需要提前终止的程度，只有5.9%（与之相比，活性药物组为87.5%）未改变地完成了8周疗程。此外，安慰剂组分别有41.17%和23.52%（与之相比，活性药物组无一人出现）出现与EPS相关的严重主诉和/或精神病症状。这些结果与突然停药研究的结果几乎相同。因此，即使药物是逐渐停用的，慢性精神分裂症患者停用AP药物似乎仍然存在问题。
